Yantai Dongcheng Pharmaceutical Group Co.,Ltd.
SZSE:002675.SZ
17.35 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 3,275.648 | 3,582.955 | 3,912.05 | 3,418.978 | 2,992.761 | 2,332.823 | 1,595.601 | 1,158.451 | 794.916 | 751.022 | 774.73 | 587.754 | 857.573 | 663.628 | 376.458 | 323.389 |
Cost of Revenue
| 1,805.958 | 2,044.375 | 2,309.876 | 1,718.778 | 1,216.521 | 995.83 | 725.429 | 612.517 | 493.275 | 502.576 | 593.456 | 413.497 | 656.158 | 565.66 | 312.145 | 277.505 |
Gross Profit
| 1,469.69 | 1,538.58 | 1,602.174 | 1,700.199 | 1,776.24 | 1,336.993 | 870.172 | 545.934 | 301.641 | 248.446 | 181.274 | 174.257 | 201.415 | 97.969 | 64.314 | 45.884 |
Gross Profit Ratio
| 0.449 | 0.429 | 0.41 | 0.497 | 0.594 | 0.573 | 0.545 | 0.471 | 0.379 | 0.331 | 0.234 | 0.296 | 0.235 | 0.148 | 0.171 | 0.142 |
Reseach & Development Expenses
| 197.223 | 163.52 | 137.558 | 109.387 | 88.713 | 64.785 | 39.82 | 27.743 | 38.144 | 36.308 | 15.359 | 5.675 | 0 | 0 | 0 | 0.314 |
General & Administrative Expenses
| 68.18 | 61.208 | 75.473 | 55.623 | 48.97 | 42.139 | 33.153 | 37.196 | 19.239 | 15.091 | 13.862 | 8.696 | 27.699 | 19.386 | 15.466 | 3.649 |
Selling & Marketing Expenses
| 507.51 | 566.12 | 592.284 | 743.417 | 832.851 | 574.401 | 333.548 | 194.921 | 80.329 | 36.033 | 17.795 | 16.168 | 11.035 | 6.803 | 6.289 | 4.305 |
SG&A
| 575.69 | 627.328 | 667.757 | 799.041 | 881.821 | 616.54 | 366.702 | 232.117 | 99.568 | 51.123 | 31.658 | 24.863 | 38.735 | 26.189 | 21.756 | 7.954 |
Other Expenses
| -23.97 | 168.809 | 150.846 | 130.564 | 137.639 | 114.799 | 86.015 | 14.438 | 6.355 | 5.016 | 28.385 | 2.43 | 6.014 | 0.783 | 1.898 | 0.837 |
Operating Expenses
| 963.295 | 959.658 | 956.16 | 1,038.991 | 1,108.173 | 796.124 | 492.536 | 317.415 | 184.756 | 129.077 | 80.777 | 55.585 | 42.732 | 26.771 | 21.867 | 16.842 |
Operating Income
| 341.662 | 448.252 | 630.319 | 609.145 | 603.942 | 467.566 | 314.169 | 228.761 | 128.174 | 126.433 | 96.619 | 122.698 | 144.811 | 59.299 | 36.468 | 16.813 |
Operating Income Ratio
| 0.104 | 0.125 | 0.161 | 0.178 | 0.202 | 0.2 | 0.197 | 0.197 | 0.161 | 0.168 | 0.125 | 0.209 | 0.169 | 0.089 | 0.097 | 0.052 |
Total Other Income Expenses Net
| -36.446 | -2.675 | -274.22 | 2.23 | -208.184 | 2.182 | 1.22 | 13.727 | 17.556 | 12.257 | 24.493 | 6.104 | -7.859 | -11.116 | -4.081 | -11.392 |
Income Before Tax
| 337.282 | 445.576 | 356.099 | 611.375 | 395.758 | 469.748 | 315.389 | 242.246 | 134.441 | 131.626 | 124.99 | 124.776 | 150.825 | 60.082 | 38.366 | 17.65 |
Income Before Tax Ratio
| 0.103 | 0.124 | 0.091 | 0.179 | 0.132 | 0.201 | 0.198 | 0.209 | 0.169 | 0.175 | 0.161 | 0.212 | 0.176 | 0.091 | 0.102 | 0.055 |
Income Tax Expense
| 83.065 | 92.76 | 95.249 | 93.902 | 102.117 | 80.955 | 50.659 | 41.931 | 22.901 | 23.76 | 21.209 | 19.84 | 22.886 | 9.455 | 6.006 | 2.54 |
Net Income
| 209.736 | 307.291 | 260.85 | 417.766 | 293.64 | 388.793 | 264.73 | 130.953 | 89.745 | 103.958 | 100.85 | 105.058 | 127.935 | 50.639 | 31.988 | 15.065 |
Net Income Ratio
| 0.064 | 0.086 | 0.067 | 0.122 | 0.098 | 0.167 | 0.166 | 0.113 | 0.113 | 0.138 | 0.13 | 0.179 | 0.149 | 0.076 | 0.085 | 0.047 |
EPS
| 0.25 | 0.38 | 0.33 | 0.52 | 0.37 | 0.51 | 0.38 | 0.2 | 0.14 | 0.2 | 0.19 | 0.23 | 0.33 | 0.13 | 0.098 | 0.069 |
EPS Diluted
| 0.25 | 0.38 | 0.33 | 0.52 | 0.37 | 0.51 | 0.38 | 0.2 | 0.14 | 0.2 | 0.19 | 0.23 | 0.33 | 0.13 | 0.098 | 0.069 |
EBITDA
| 634.047 | 714.216 | 745.25 | 771.068 | 699.993 | 621.137 | 413.808 | 309.833 | 178.003 | 161.833 | 143.544 | 129.172 | 167.747 | 75.717 | 48.903 | 33.451 |
EBITDA Ratio
| 0.194 | 0.199 | 0.191 | 0.226 | 0.234 | 0.266 | 0.259 | 0.267 | 0.224 | 0.215 | 0.185 | 0.22 | 0.196 | 0.114 | 0.13 | 0.103 |